{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:22:11Z","timestamp":1791379331011,"version":"4.3.2"},"reference-count":40,"publisher":"MedWorks Media","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>We present the case of a young gentleman admitted to an inpatient psychiatric ward with a diagnosis of Bipolar Affective Disorder who developed Valproate-induced Hyperammonaemic Encephalopathy (VHE) alongside infection with COVID-19. His condition had exhibited a relapsing and remitting course, relapses being associated with non-compliance with prescribed medication and substance misuse. He had previously been successfully treated with a combination of antipsychotic (haloperidol) and semi-sodium valproate which were re-prescribed following the index admission to hospital. On this occasion however both his mental and physical health began to deteriorate, with evidence of irritability and over-sedation, disorientation, and significantly impaired cognition. On examination, reduction in visual fields was noted, and after bloods, MRI scanning and a review by neurology, he was diagnosed with hyperammonaemic encephalopathy. This was suspected to be an adverse effect of the Depakote. Following transfer back to the psychiatric hospital, he was cross titrated off Depakote and on to Lithium, and the cognitive disturbance remitted. This case adds to the existing literature on the potential challenges in diagnosing this rare but potentially fatal reaction to valproate, in a psychiatric inpatient population for which data on VHE is limited. Psychiatrists should keep a high index of suspicion for VHE in those taking Valproate who show new signs of a deterioration in mental status. Early diagnosis and withdrawal of valproate are key in manifesting a prompt and complete recovery. While neurologists are familiar with this complication we believe this is not well known among psychiatrists and therefore worthy of adding this case report to the existing literature.<\/jats:p>","DOI":"10.64719\/pb.16617","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:16:27Z","timestamp":1773260187000},"page":"191-198","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Valproate Induced Hyperammonaemic Encephalopathy in a Psychiatric Inpatient"],"prefix":"10.64719","volume":"56","author":[{"given":"Alice","family":"Cockill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"ref1","unstructured":"Sodium valproate. In: Joint Formulary Committee. British National Formulary [Internet]. London: BMJ Group and Pharmaceutical Press; [updated 2025 Feb 11; cited 2025 Jul 15]. Available from: https:\/\/bnf.nice.org.uk\/drugs\/sodium-valproate\/#side-effects."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Chang HH, Yang YK, Gean PW, Huang HC, Chen PS, Lu RB. The role of valproate in metabolic disturbances in bipolar disorder patients. Journal of Affective Disorders. 2010;124(3):319\u2013323.","DOI":"10.1016\/j.jad.2009.12.011"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Cheng M, Tang X, Wen S, Yue J, Wang H. Valproate (VPA)-associated hyperammonemic encephalopathy independent of elevated serum VPA levels: 21 cases in China from May 2000 to May 2012. Comprehensive Psychiatry. 2013;54:562\u2013567.","DOI":"10.1016\/j.comppsych.2012.11.001"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Raja M, Azzoni A. Valproate-induced hyperammonaemia. Journal of Clinical Psychopharmacology. 2002;22(6):631\u2013633.","DOI":"10.1097\/00004714-200212000-00019"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Chauhan V, Dixit S, Goyal S, Azad S. Valproate induced hyperammonemic encephalopathy treated by haemodialysis. Industrial Psychiatry Journal. 2017;26:99.","DOI":"10.4103\/ipj.ipj_37_16"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Yildizhan E, Tomruk NB, \u00d6zdemir A et al. Role of valproate in hyperammonemic encephalopathy in women in a tertiary psychiatric clinic. Anadolu Psikiyatri Dergisi. 2019;20:589\u2013596.","DOI":"10.5455\/apd.33226"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Segura-Bruna N, Rodriguez-Campello A, Puente V, Roquer J. Valproate-induced hyperammonemic encephalopathy. Acta Neurologica Scandinavica. 2006;114:1\u20137.","DOI":"10.1111\/j.1600-0404.2006.00655.x"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Dixit S, Namdeo M, Azad S. Valproate induced delirium due to hyperammonemia in a case of acute mania: a diagnostic dilemma. Journal of Clinical and Diagnostic Research. 2015;9(4):VD01\u2013VD02.","DOI":"10.7860\/JCDR\/2015\/11830.5758"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Dealberto MJCC. Valproate-induced hyperammonaemic encephalopathy: review of 14 cases in the psychiatric setting. International Clinical Psychopharmacology. 2007;22:330\u2013337.","DOI":"10.1097\/YIC.0b013e3281c61b28"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Stewart JT. A case of hyperammonemic encephalopathy after 11 years of valproate therapy. Journal of Clinical Psychopharmacology. 2008;28:361\u2013362.","DOI":"10.1097\/JCP.0b013e31817275b6"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Din\u00e7er M, Akg\u00fcn A, Bodur \u015e et al. Hyperammonemic encephalopathy without hepatic dysfunction due to treatment with valproate: four cases and a mini review. Psychiatry and Clinical Psychopharmacology. 2018;28(4):448\u2013460.","DOI":"10.1080\/24750573.2018.1448133"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Wadzinski J, Franks R, Roane D, Bayard M. Valproate-associated hyperammonemic encephalopathy. Journal of the American Board of Family Medicine. 2007;20:499\u2013502.","DOI":"10.3122\/jabfm.2007.05.070062"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Coppola G, Epifanio G, Auricchio G, Federico RR, Resicato G, Pascotto A. Plasma free carnitine in epilepsy children, adolescents and young adults treated with old and new antiepileptic drugs with or without ketogenic diet. Brain and Development. 2006;28:358\u2013365.","DOI":"10.1016\/j.braindev.2005.11.005"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Chopra A, Kolla BP, Mansukhani MP, Netzel P, Frye MA. Valproate-induced hyperammonemic encephalopathy: an update on risk factors, clinical correlates and management. General Hospital Psychiatry. 2012;34:290\u2013298.","DOI":"10.1016\/j.genhosppsych.2011.12.009"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Lewis C, Tesar GE, Dale R. Valproate-induced hyperammonemic encephalopathy in general hospital patients with one or more psychiatric disorders. Psychosomatics. 2017;58:415\u2013420.","DOI":"10.1016\/j.psym.2017.02.003"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Verrotti A, Trotta D, Morgese G, Chiarelli F. Valproate-induced hyperammonemic encephalopathy. Metab Brain Dis. 2002;17(4):367\u2013373.","DOI":"10.1023\/A:1021918104127"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Yamamoto Y, Takahashi Y, Imai K et al. Risk factors for hyperammonemia in pediatric patients with epilepsy. Epilepsia. 2013;54:983\u2013989.","DOI":"10.1111\/epi.12125"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Lheureux PER, Penaloza A, Zahir S, Gris M. Science review: carnitine in the treatment of valproic acid-induced toxicity \u2013 what is the evidence? Critical Care. 2005;9:431\u2013440.","DOI":"10.1186\/cc3742"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Butterworth RF. Effects of hyperammonaemia on brain function. Journal of Inherited Metabolic Disease. 1998;21:6\u201320.","DOI":"10.1023\/A:1005393104494"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Lewis C, Deshpande A, Tesar GE, Dale R. Valproate-induced hyperammonemic encephalopathy: a brief review. Current Medical Research and Opinion. 2012;28:1039\u20131042.","DOI":"10.1185\/03007995.2012.694362"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Hocaoglu DN, Ozsoy S, Bulut K, Ismailogullari S, Erdogan M. Valproic acid-induced hyperammonemic encephalopathy. Dusunen Adam J Psychiatr Neurol Sci. 2020;33(2):218\u2013220. doi: 10.14744\/DAJPNS.2020.00083.","DOI":"10.14744\/DAJPNS.2020.00083"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Oechsner M, Steen C, St\u00fcrenburg HJ, Kohlsch\u00fctter A. Hyperammonaemic encephalopathy after initiation of valproate therapy in unrecognised ornithine transcarbamylase deficiency. Journal of Neurology Neurosurgery and Psychiatry. 1998;64:680\u2013682.","DOI":"10.1136\/jnnp.64.5.680"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Norenberg MD, Rama Rao KV, Jayakumar AR. Mechanisms of ammonia-induced astrocyte swelling. Metab Brain Dis. 2005;20(4):303\u2013318.","DOI":"10.1007\/s11011-005-7911-7"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Carr RB, Shrewsbury K. Hyperammonemia due to valproic acid in the psychiatric setting. American Journal of Psychiatry. 2007;164:1020\u20131027.","DOI":"10.1176\/ajp.2007.164.7.1020"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Dawson LP, Lee SJ, Hollander YS. Valproate-induced hyperammonemic encephalopathy associated with urinary tract infection and urinary retention in the psychiatric setting. Australian and New Zealand Journal of Psychiatry. 2016;50:1110. SAGE Publications Inc.","DOI":"10.1177\/0004867416640906"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Sabe M, Dorsaz O, Huguelet P, Kaiser S. Toxicity of psychotropic drugs in patients with COVID-19: a systematic review. 2021;70:1\u20139. General Hospital Psychiatry [Internet] Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163834321000268.","DOI":"10.1016\/j.genhosppsych.2021.02.006"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Rath A, Naryanan T, Chowdhary G, Murthy J. Valproate-induced hyperammonemic encephalopathy with normal liver function. Neurol India. 2005;53(2):226\u2013228.","DOI":"10.4103\/0028-3886.16420"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Lheureux PER, Hantson P. Carnitine in the treatment of valproic acid-induced toxicity carnitine in VPA toxicity. Clinical Toxicology. 2009;47:101\u2013111.","DOI":"10.1080\/15563650902752376"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Nicolai J, Smith S, Keunen R. Simultaneous side effects of both clozapine and valproate. Intensive Care Medicine. 2001;27(5):943.","DOI":"10.1007\/s001340100937"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Eyer F, Felgenhauer N, Gempel K, Steimer W, Gerbitz KD, Zilker T. Acute valproate poisoning: pharmacokinetics, alteration in fatty acid metabolism, and changes during therapy. Journal of Clinical Psychopharmacology. 2005;25:376\u2013380.","DOI":"10.1097\/01.jcp.0000168485.76397.5c"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Kumar A, Suri A, Sharma BS. Severe valproate induced hyperammonemic encephalopathy successfully managed with peritoneal dialysis. Indian Journal of Critical Care Medicine. 2014;18(7):461\u2013463.","DOI":"10.4103\/0972-5229.136076"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Hawkes ND, Thomas GAO, Jurewicz A et al. Non-hepatic hyperammonaemia: an important, potentially reversible cause of encephalopathy. Postgraduate Medical Journal. 2001;77:717\u2013722.","DOI":"10.1136\/pmj.77.913.717"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Vossler DG, Wilensky AJ, Cawthon DF et al. Serum and CSF glutamine levels in valproate-related hyperammonemic encephalopathy. Epilepsia. 2002;43:154\u2013159.","DOI":"10.1046\/j.1528-1157.2002.25001.x"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Eze E, Workman M, Donley B. Hyperammonemia and coma developed by a woman treated with valproic acid for affective disorder. Psychiatric Services. 1998;49:1358\u20131359.","DOI":"10.1176\/ps.49.10.1358"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Dealberto MJCC, Sarazin FFA. Valproate-induced hyperammonemic encephalopathy without cognitive sequelae: a case report in the psychiatric setting. Journal of Neuropsychiatry and Clinical Neurosciences. 2008;20(3):369\u2013371.","DOI":"10.1176\/jnp.2008.20.3.369"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Gerstner T, Buesing D, Longin E et al. Valproic acid induced encephalopathy \u2013 19 new cases in Germany from 1994 to 2003 \u2013 A side effect associated to VPA-therapy not only in young children. Seizure. 2006;15:443\u2013448.","DOI":"10.1016\/j.seizure.2006.05.007"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Davoudi-Monfared E, Radmehr M, Ghaeli P, Mousavi M. A case series of severe hyperammonemia encephalopathy related to valproate: can antipsychotics increase the risk? Iranian Journal of Psychiatry. 2019;14:248\u2013252.","DOI":"10.18502\/ijps.v14i3.1342"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Imbert-Bismut F, Payet PE, Alfaisal J et al. Transportation and handling of blood samples prior to ammonia measurement in the real life of a large university hospital. Clinica Chimica Acta. 2020;510:522\u2013530.","DOI":"10.1016\/j.cca.2020.07.048"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Cooper AJL. Role of glutamine in cerebral nitrogen metabolism and ammonia neurotoxicity. Mental Retardation and Developmental Disabilities Research Reviews. 2001;7:280\u2013286.","DOI":"10.1002\/mrdd.1039"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Kimmel RJ, Irwin SA, Meyer JM. Valproic acid-associated hyperammonemic encephalopathy: a case report from the psychiatric setting. International Clinical Psychopharmacology. 2005;20:57\u201358.","DOI":"10.1097\/00004850-200501000-00012"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:36:59Z","timestamp":1791315419000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/case-report-valproate-induced-hyperammonaemic-encephalopathy-in-a-psychiatric-inpatient\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,3,9]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.16617","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]}}}